Cervicofacial synovialosarcoma is a malignant tumor. It poses a diagnostic and therapeutic problem. Synovialosarcoma has the strongest recurrence power among soft tissue sarcomas. These recurrences are more frequent during the first two years. Distant metastases are seen in 30% to 50% of cases and are mainly pulmonary.We report the observation of a young 38-year-old patient who was operated on in 2013 for synovialosarcoma oropharynx with radiotherapy postoperatively 6 years after the patient has two recurrences, one oropharyngeal and the other cervical.
ORIGINAL RESEARCH ARTICLE | Oct. 29, 2020
Hydroxychloroquine and Management of COVID-19 What is behind its Accurate Detection in its Pharmaceutical Products?
Sara A. R, Eslam M. Shehata, Mohamed Raslan, Nagwa A. Sabri
Background: Hydroxychloroquine Sulphate, is an antimalarial drug used in treatment and prophylaxis of malaria, and other conditions like rheumatoid arthritis, and tried as a prophylaxis of venous thromboembolism. It is one of the important choices in COVID-19 management, as shown by about 80% improvement in pneumonia, and prevention of further disease progression to severe conditions upon following Hydroxychloroquine therapeutic regimen. Aim: The aim of this work was to develop an economical, precise, accurate and specific analytical method for quantitative estimation of Hydroxychloroquine sulphate in pharmaceutical product for the purpose of using it as a quality control tool for testing Hydroxychloroquine sulphate products pre-market and post-market distribution. Insuring the presence of labelled drug amount in the dosage from. Methods: Determination of HQC in commercial pharmaceutical formulations dispensed in hospitals and community pharmacies and administered by patients, by in house development of a validated, selective and sensitive High Performance Liquid Chromatography (HPLC) test method, where, the procedure used is in accordance with published literature data, pharmacopeia, and international guidelines. Results: The method is specific and selective, and showed linearity R2>0.999 within concentration range of 25-300 µg/mL, accuracy results within the range of 98% - 102%, precision CV% less than 2%. The assayed tablets mean recovery are 99.045%. Moreover, dissolution results are fulfilling the required limit of 70% percent dissolution within 60 minutes. Conclusion: The in-house developed analytical method is easy, and cost effective for use in quantification of HQC.
REVIEW ARTICLE | Oct. 29, 2020
Management of Second Wave of COVID 19 with Ledipasvir / Sofosbuvir Combination. Will it Work? A Review Article
Sara A. Raslan, Eslam M. Shehata, Mohamed Raslan, Nagwa A. Sabri
The COVID-19 epidemic has already exerted a wide effect on the global level and the rapid growth of infected cases resulted in an overwhelmed health care providing systems. Many countries that have already peaked and flattened the infection curve reached now the minimum infection rate and minimal or zero reporting of new cases. As a consequence, many countries are reducing their precautionary measures which might lead to the emerging of a second incidence wave of SARS-CoV-2. On the other hand, direct antiviral combination therapy as Ledipasvir/Sofosbuvir showed sufficient efficacy in treatment of chronic hepatitis C virus (HCV) with an acceptable safety profile showing a minimum side effect and well tolerated upon administration during the treatment time course as well. Besides, according to published studies and collected data, this combination recorded a minimal drug interactions with the other therapeutic agents used for the management of co-morbid conditions with COVID-19. Finally, the reported results of performed studies showed a superior time to clinical recovery from COVID-19 for Sofosbuvir / Daclatasvir regmin over that of Lopinavir/ritonavir, and thus, the proposal of involving Ledpasvir/Sofosbuvir combination as a better treatment option than other direct antiviral agents in the management of COVID-19 for the second wave.
ORIGINAL RESEARCH ARTICLE | Oct. 29, 2020
FTIR Based Pharmacological Validation of Bridelia retusa
Bridelia retusa commonly known as Khaja or Kasai in India, belonging to the family Euphorbiaceae, is a tropical small-sized tree found throughout warmer parts of India. Entire parts of Bridelia retusa has been traditionally used for healing of several ailments such as rheumatism, diabetes, diarrhea, dysentery, removal of urinary concretions, and the bark of the plant is used by tribal people to develop sterility as a contraceptive. The present investigation was planned to evaluate and explore potential bioactive phytocompounds in the bark, fruit, and leaf extract of Bridelia retusa using phytochemical profiling and an infra-red spectrophotometer. The phytochemical evaluation of bark, fruit, and leaf extracts of Bridelia retusa revealed the presence of alkaloids, cardiac glycosides, flavonoids, saponins, steroids, tannins, and terpenoids in extracts. All seven phytocompounds were found in both aqueous leaf and methanolic bark extracts. Alkaloid was detected in all except for ethyl acetate extract. Cardiac glycosides were found in extracts of aqueous and petroleum ether. Steroid and terpenoids were detected from all aqueous and methanol extracts whereas saponin was found in all aqueous extracts. FTIR spectrophotometric analysis exhibited the presence of primary & secondary alcohols, alkenes, aldehyde, primary & secondary amines, aliphatic bromo compounds, aliphatic ether, aromatic amines, acid halides, ester, halo compounds, vinyl ether, and aromatic compounds. The presence of these phytocompounds suggests better possibilities for the plant as a source of significant phytomedicines in pharmaceutical industries and research institutes for the discovery of lead compounds for a competent drug.
Scholars Middle East Publishers
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.